Harry Sokol

Plain English
This study looked at how certain cells in the intestines, called GLP-1 cells, are affected by inflammation in diseases like Crohn’s disease. Researchers found that the numbers of these GLP-1 cells were significantly lower in both mice with intestinal inflammation and in patients with Crohn’s, suggesting that inflammation may disrupt their normal function. Since GLP-1 is important in regulating metabolism and inflammation, reducing these cells could worsen symptoms, making it critical to explore them as a possible treatment target. Who this helps: This helps patients with inflammatory bowel diseases.

Plain English
This study looked at how using antibiotics affects the effectiveness of biologic treatments for psoriasis over time. Researchers found that among 36,129 patients, those who used antibiotics had a higher risk of stopping their biologic therapy. Specifically, 25.9% of patients were on antibiotics before starting treatment, and during follow-up, the risk of discontinuing therapy increased by 12% for those exposed to antibiotics, rising to 29% for those who used multiple antibiotics. Who this helps: This information is valuable for patients with psoriasis and their doctors, guiding treatment decisions.

Plain English
This study investigated how certain viruses called bacteriophages move across the intestinal wall in both healthy individuals and those with Crohn's disease. The researchers found that in Crohn's disease patients, there are more viral particles in their blood that come from the gut, indicating a breakdown in the intestinal barrier. Specifically, they noted that the presence of these viruses is significantly higher in Crohn's patients than in healthy ones, suggesting that the disease allows more viruses to enter the bloodstream. Who this helps: This information helps patients with Crohn's disease and their doctors understand the role of viruses in their condition.

Plain English
This study focused on a gut bacterium called Faecalibacterium prausnitzii, which is important for health and tends to be lower in people with inflammatory bowel disease (IBD). Researchers found that when human immune cells were exposed to F prausnitzii, they produced a key anti-inflammatory molecule (IL10) without triggering an inflammatory response, specifically in certain immune cells called monocytes. This response also changed how these cells manage energy, indicating how F prausnitzii may help reduce inflammation in conditions like IBD. Who this helps: This benefits patients with inflammatory bowel disease and their doctors.

Plain English
Researchers analyzed the use of fecal microbiota transplantation (FMT) in France from 2019 to 2022 for patients with serious conditions where standard treatments failed. Out of 67 requests, 54 were approved and 40 procedures were done, with a success rate of 37.5%. Specifically, FMT was most effective in treating severe graft-versus-host disease (53% success), but results were less promising for other conditions like multidrug-resistant infections (31% success). Who this helps: This benefits patients with severe health issues lacking effective treatment options.

Plain English
This study looked at how the germs that live in the intestines change in patients with Crohn's disease after they undergo surgery. Researchers found that while surgery slightly alters these germs, specific changes were significant: for example, the beneficial gut bacteria Faecalibacterium prausnitzii decreased, while another bacteria, Akkermansia muciniphila, increased after surgery. Understanding these changes is important because they could help predict when and how Crohn's disease might come back after surgery. Who this helps: This research helps patients with Crohn's disease and their doctors manage the risk of disease recurrence after surgery.

Plain English
This study examined how often Crohn's disease returns after surgery and the effectiveness of preventive biologic treatments. Out of 632 patients who had surgery, 37.5% experienced a return of the disease within a year, with factors like being male, smoking, and prior surgeries increasing that risk. Importantly, patients who received preventive biologic treatments had a much lower risk of recurrence, reducing it by 69%. Who this helps: This research benefits patients with Crohn's disease who are considering surgery, as well as their doctors in making treatment decisions.

Plain English
This study looked at how diet and gut bacteria affect inflammatory bowel disease (IBD), a condition that causes long-lasting inflammation in the digestive system. It found that changing diet and using treatments that alter gut bacteria, like probiotics and fecal transplants, can improve symptoms of IBD. The researchers highlighted the need for personalized approaches to treatment, which could help people manage their condition more effectively. Who this helps: This benefits patients with inflammatory bowel disease.

Plain English
This study looked at how different clinical practices and patient conditions affect the success of fecal microbiota transplantation (FMT) for treating Clostridioides difficile infections. Out of 658 procedures over five years, 84.3% were successful, although some factors like severe chronic kidney disease and poor bowel preparation increased the risk of treatment failure. These findings highlight the importance of customizing treatment procedures to improve outcomes for patients. Who this helps: This helps patients with recurrent Clostridioides difficile infections and the healthcare providers treating them.

Plain English
This research reviewed studies examining the gut bacteria and their byproducts in relation to valvular heart disease (VHD). It found that patients with calcific aortic stenosis (a type of VHD) had high levels of a compound called TMAO, which is associated with a greater risk of heart problems, while changes in gut bacteria were noted in patients with rheumatic and Barlow's mitral valve diseases. Understanding these links is important because it could lead to new ways to predict and treat heart conditions linked to gut health. Who this helps: Patients with heart valve diseases and their doctors.

Plain English
This study investigated how changes in the sugars on the surface of the gut lining affect the balance of gut bacteria and the immune response, which can lead to intestinal inflammation and diseases like Inflammatory Bowel Disease (IBD). The researchers found that in specially-engineered mice, these changes caused a drop in beneficial gut bacteria and a shift in immune cells related to inflammation. Specifically, they observed a 60% decrease in certain bacteria and a significant rise in inflammatory signals in the gut. This is important because it helps explain how the gut environment can contribute to inflammation and provides evidence that restoring the sugar balance can help protect against IBD. Who this helps: This research benefits patients with IBD and healthcare providers by identifying potential new treatment strategies.

Plain English
This study examined the link between gut health and a specific type of hand osteoarthritis called erosive hand osteoarthritis (EHOA). Researchers analyzed blood samples from 410 patients and discovered that those with EHOA had higher levels of certain gut-related proteins (LBP and ZRP) compared to those without the condition. The findings showed that elevated levels of these proteins are connected to both the severity of osteoarthritis symptoms and joint damage, indicating that gut health might play an important role in osteoarthritis. Who this helps: This helps patients suffering from hand osteoarthritis and their doctors in understanding potential underlying factors affecting their condition.

Plain English
This study looked at how aging affects the gut bacteria and related substances in hamsters infected with COVID-19. Researchers found that older hamsters (22 months old) had significant changes in their gut microbiota and certain metabolites, which were linked to more severe disease and slower recovery compared to younger hamsters (2 months old). Specifically, older hamsters showed a consistent drop in important compounds, such as phenylalanine and tryptophan, which were associated with worse recovery and lung issues. Who this helps: This research benefits elderly patients by highlighting potential new treatments for COVID-19 that target gut health.

Plain English
This study looked at whether a common gut parasite, Dientamoeba fragilis, can be passed between people during fecal microbiota transplants (FMT) used to treat recurring Clostridioides difficile infections. Researchers found that although 18.7% of healthy donors had this parasite, it did not spread to patients receiving their donations, and the treatment success rates were similar for patients receiving donations with or without the parasite—95.5% for D. fragilis-positive and 93.6% for negative. This research shows that it is safe to use stool from D. fragilis-positive donors, which will make it easier to find suitable donors and improve the efficiency of the FMT process. Who this helps: This helps patients undergoing treatment for recurring C. difficile infections.

Plain English
This study looked at a combination of two drugs, regorafenib and avelumab, to treat advanced gastroenteropancreatic neuroendocrine tumors, which are difficult to treat. Out of 47 patients, 42 were assessed, and the results showed that 18% had a positive response six months into the treatment, with patients experiencing progression-free survival for an average of 5.5 months. These findings are important because they suggest that this combination therapy could offer a new treatment option for patients with these challenging tumors while identifying specific biomarkers that could help predict treatment success. Who this helps: Patients with advanced gastroenteropancreatic neuroendocrine tumors.

Plain English
This study looked at different types of a gut bacteria called Faecalibacterium in both healthy people and those with Crohn's disease, a condition that causes inflammation in the intestines. Researchers found that healthy individuals had a rich variety of Faecalibacterium, with specific species being present in high numbers (up to 10 billion bacteria per gram of stool), while Crohn's disease patients had significantly lower levels, with some bacteria absent altogether. The findings highlight that maintaining healthy levels of certain Faecalibacterium species may be important in managing Crohn's disease, as one species, Faecalibacterium prausnitzii, was more common in patients whose symptoms were under control. Who this helps: Patients with Crohn's disease and their doctors.

Plain English
This study looked at how the bacteria in our guts affect the effectiveness of a specific cancer treatment called CAR T-cell therapy for patients with lymphoma. Researchers found that patients receiving this treatment had a drop in helpful bacteria, especially Akkermansia, which was linked to poorer outcomes. By giving patients a supplement with Akkermansia, the therapy worked better, increasing the CAR T-cells’ ability to target tumors. Who this helps: This benefits lymphoma patients undergoing CAR T-cell therapy.

Plain English
This study examined the gut bacteria of 200 COVID-19 patients and 102 healthy individuals in Morocco and France to see how gut health relates to the severity of COVID-19 symptoms. Researchers found that COVID-19 patients had notable changes in their gut bacteria, especially those with severe illness; for example, certain biological pathways linked to gut function were disrupted. This matters because understanding these changes could lead to new ways to assess and manage COVID-19 severity. Who this helps: This helps patients and doctors in managing COVID-19 and understanding its effects on overall health.

Plain English
This paper studied how to improve microbiome research, focusing on the roles of gut bacteria in health and disease. The authors found that while new technologies like artificial intelligence (AI) hold promise for better understanding these relationships, there are still many challenges in proving cause-and-effect connections and ensuring the reliability of results. It matters because improving these studies can lead to better healthcare decisions and personalized treatments based on microbiome insights. Who this helps: This benefits patients and healthcare providers looking for more precise and effective treatments.

Plain English
This study looked at different methods of fecal microbiota transplantation (FMT) to see which is most effective for treating ulcerative colitis (UC). It found that a combination of lower gastrointestinal FMT and oral capsules was the most effective, with a relative risk of 12.5 for achieving clinical remission, compared to other methods like upper GI FMT. This matters because it helps identify the best treatment options for patients with UC, potentially improving their quality of life. Who this helps: Patients with ulcerative colitis.

Plain English
This study looked at a new type of activated carbon made from food waste that can remove sulfur from liquid fuels like jet fuel and diesel. Researchers found that this renewable carbon material adsorbed more sulfur than traditional commercial options, making it a promising solution for creating cleaner fuels. This matters because reducing sulfur in fuels can lead to lower emissions of harmful pollutants, helping to improve air quality. Who this helps: This benefits fuel producers and environmental agencies aiming to reduce pollution.

Plain English
This study examined how a substance called cadaverine, produced by gut bacteria, affects immune cells called macrophages and their role in colon inflammation. The researchers found that at low levels, cadaverine helps macrophages reduce inflammation, while at higher levels, it can trigger inflammation instead. This is important because in patients with inflammatory bowel disease (IBD), higher levels of cadaverine are linked to a greater risk of experiencing flare-ups. Who this helps: This information benefits patients with inflammatory bowel disease and their doctors.

Plain English
This study looked at a type of cell in the intestine that produces a hormone called GLP-1, which helps control metabolism and inflammation. Researchers found that in both mice with intestinal inflammation and people with Crohn's disease, the number of GLP-1 cells was significantly lower in the affected areas. Specifically, they observed a consistent reduction in these cells during inflammation, suggesting that GLP-1 might play an important role in managing intestinal inflammation and could be a potential target for new treatments for inflammatory bowel diseases. Who this helps: Patients with inflammatory bowel diseases like Crohn's disease.

Plain English
This study evaluated four different blood tests available in Europe to accurately diagnose amoebic abscesses, a severe liver infection caused by a parasite. Researchers tested these kits on 442 serum samples, finding that the sensitivity of the tests ranged from 87.3% to 97.5% and specificity ranged from 78.3% to 98.6%. The best combination of tests included the Bordier ELISA for initial screening and the ELITex Bicolor for confirmation, which can significantly improve patient diagnosis and treatment. Who this helps: This helps doctors and clinical microbiologists improve how they diagnose patients with potentially life-threatening amoebic infections.

Plain English
This study looked at how a substance called indole-3-propionic acid (IPA), produced by gut bacteria, influences immune cells known as CD4 T cells, especially in relation to inflammation in the gut. The researchers found that IPA boosts the energy production in these T cells by encouraging the use of fats and proteins for fuel while reducing the use of sugars. In tests with mice, giving IPA helped improve T cell function and protect against gut inflammation. Who this helps: This benefits patients with gut inflammation and immune-related conditions.

Plain English
This study focuses on the gut microbiome, which is a collection of microorganisms in the digestive system, and its role in inflammatory bowel disease (IBD), including conditions like Crohn's disease and ulcerative colitis. Researchers found that imbalances in the gut microbiome can contribute to these diseases by affecting the immune system and causing inflammation. New treatments are being developed to change the gut bacteria in a more targeted way, including specialized probiotics and other therapeutic products, as a promising approach to manage IBD more effectively. Who this helps: This helps patients with inflammatory bowel diseases who need better treatment options.

Plain English
This research studied how different lifestyle factors, like age, smoking, and weight, affect groups of bacteria living in the guts of 938 healthy people. The findings showed that older individuals and smokers had fewer bacterial groups that worked well together, while those with higher body weight had more interconnected bacterial groups. This matters because understanding these relationships could lead to better insights into how our gut bacteria influence overall health and disease. Who this helps: This helps patients by providing insights into the health effects of lifestyle choices on gut bacteria.

Plain English
This study investigated the effects of the probiotic CNCM I-745 on the gut microbiome when antibiotics are used. Researchers found that this probiotic helped maintain the balance of gut bacteria and supported the production of important compounds linked to immune health, especially when antibiotics like amoxicillin/clavulanic acid were used. Specifically, it reduced inflammation in immune cells exposed to changed gut bacteria, showing that CNCM I-745 can help keep the gut healthier during antibiotic treatment. Who this helps: This benefits patients taking antibiotics and healthcare providers looking for ways to manage antibiotic side effects.

Plain English
This study examined how gut bacteria affect the metabolism of tryptophan, an important amino acid, in mice. Researchers found that the gut microbiota significantly influences tryptophan metabolism, and when grouping bacterial types together, it provided better insights than looking at each type separately. This understanding is crucial because it highlights how gut microbes can impact overall health through their effects on tryptophan-related substances. Who this helps: This benefits patients with gastrointestinal issues, as well as researchers studying the gut microbiome and its effects on health.

Plain English
This study focused on improving the analysis of gut microbiome data, which is important for understanding human health. Researchers developed a new tool called TaxaPLN that creates artificial microbiome profiles while keeping their natural characteristics. The results showed that this method not only maintains the quality of the data but also improves predictions in most cases, making it more effective than previous approaches. Who this helps: This benefits researchers and healthcare professionals studying gut health and related diseases.

Plain English
This paper studied how the research on microbiomes, which are the tiny organisms living in our bodies, can be used in medical practice. It found that while there is promising evidence for using microbiomes to help diagnose and treat diseases, such research is not yet part of standard medical care. The authors emphasize the need for better communication between researchers and doctors, as well as improvements in research methods. Who this helps: This benefits patients by potentially providing new ways to diagnose and treat their health issues.

Plain English
This study focused on the growing interest in using gut microbiome tests in healthcare but found that current evidence for their effectiveness is lacking. An expert panel was formed to create guidelines for how these tests should be used to ensure that they are reliable, safe, and valuable in a clinical setting. Their goal is to avoid wasting resources on tests that don’t help patients and to improve the overall quality of healthcare involving microbiome diagnostics. Who this helps: This helps patients and healthcare providers by ensuring that microbiome tests are effective and properly regulated.

Plain English
This study looked at fecal microbiota transplantation (FMT) as a treatment for ulcerative colitis, a type of inflammatory bowel disease. Experts found that while FMT has shown promise in helping patients with this condition, there is still a need for more thorough clinical trials to properly assess its effectiveness. They highlighted the importance of creating standardized methods for future studies, which could lead to better treatment options and improved health outcomes for patients. Who this helps: This helps patients with ulcerative colitis seeking new treatment options.

Plain English
This study examined how the gut microbiome affects the effectiveness of certain cancer treatments called immune checkpoint inhibitors (ICIs). Researchers found that a specific strain of bacteria, EXL01, improved cancer treatment responses in patients with non-small cell lung cancer and melanoma. In experiments, this strain helped restore the anti-cancer response when antibiotics disrupted the gut microbiome, which is important for making these treatments more effective. Who this helps: This research benefits cancer patients receiving immune checkpoint inhibitors.

Plain English
This study focused on how the body processes an amino acid called tryptophan (Trp) and its effects on heart disease in mice. Researchers found that a high-fat diet increased the activity of an enzyme that changes Trp metabolism, leading to inflammation and worsening atherosclerosis, a condition where arteries become clogged. When they inhibited serotonin production or added specific compounds from the Trp pathway, the mice showed reduced inflammation and improved atherosclerosis. Who this helps: This research benefits patients at risk of heart disease and doctors looking for new treatment options.

Plain English
This study looked at two methods for preparing fecal transplants to treat a recurrent infection called rCDI. The researchers found that frozen native feces preparation had an 86.7% success rate, while the standard frozen preparation had a 76.7% success rate. This means using the new method is not only effective but also saves resources, which is important in managing and treating this infection. Who this helps: This benefits patients with recurrent infections and healthcare providers involved in their treatment.

Plain English
This study looked at how an alternating high-fat diet (HFD) affects the development of atherosclerosis, a condition where arteries become clogged. Researchers found that mice on an alternating HFD developed atherosclerosis faster than those on a consistent high-fat diet, showing a significant increase in inflammatory responses and neutrophil levels. Specifically, neutrophils, a type of immune cell, contributed to worsening artery health by seeping into plaque and creating traps that harm blood vessels. Who this helps: This research benefits patients at risk for heart disease, helping doctors understand how diet changes can impact their cardiovascular health.

Plain English
This study looked at the long-term outcomes for patients with Crohn's disease who had surgery to remove part of their intestine (ileal resection) soon after their diagnosis. Researchers found that those who had surgery within six months had a 10-year chance of needing another surgery (25%) similar to those who had surgery later (about 22% for late surgery), and they needed less follow-up treatment after surgery compared to those who waited longer (3.7 years vs. 0.9 years). This is important because it suggests that early surgery may not lead to worse outcomes and might reduce the need for more treatments later on. Who this helps: This helps patients with Crohn's disease by providing evidence that early surgery can be a good option without increasing long-term risks.

Plain English
This study examined how daily exposure to a harmful toxin from blue-green algae, called microcystin-LR (MC-LR), affects inflammation and gut bacteria in mice over a year. The researchers found that this exposure caused changes in gut bacteria, leading to inflammation throughout the body, with a significant increase in inflammatory markers. Specifically, changes in certain gut bacteria (like Muribaculaceae) were linked to promoting inflammation, while others (like Lachnospiraceae) seemed to reduce it. This is important because understanding these gut responses could help in developing ways to manage chronic diseases caused by toxins in drinking water. Who this helps: This helps patients exposed to environmental toxins and doctors who treat related chronic inflammatory diseases.

Plain English
This study looked at how melatonin can help male dairy goats suffering from reduced sperm quality due to heat stress. The researchers found that melatonin improved sperm quality by lowering inflammation and oxidative stress, and it also helped restore healthy gut bacteria, which is important for sperm production. These findings are significant because they provide a way to enhance the reproductive performance of male dairy goats, which can improve overall livestock productivity. Who this helps: This helps dairy goat farmers and livestock producers.

Plain English
This study looked at how aging affects the gut bacteria and metabolites in hamsters infected with COVID-19, comparing young (2 months old) and older (22 months old) hamsters. Researchers found that older hamsters had significant changes in their gut bacteria and lower levels of certain substances linked to poor recovery from the disease. For example, older hamsters showed decreased levels of amino acids like phenylalanine and tryptophan, which were associated with more severe disease outcomes. These findings highlight the importance of considering age when treating viral pneumonia to improve recovery and long-term health. Who this helps: This helps patients, especially older adults, by informing better treatment strategies for COVID-19.

Plain English
This study examined the tiny organisms living in the small intestine (duodenojejunal microbiome) and how they relate to obesity and nutrition, comparing them with those found in the mouth and stool. Researchers analyzed samples from 30 participants, half of whom had obesity, and found that individuals with obesity had a more diverse set of these intestinal microbes. This research shows that the small intestine's microbiome plays a significant role in dietary habits and metabolic health, and it might be more important than previously thought when addressing obesity-related issues. Who this helps: This helps patients struggling with obesity and healthcare providers looking for new ways to improve weight management.